Kygent Therapeutics
- Biotech or pharma, therapeutic R&D
Kygent Therapeutics (Shanghai, 2021), a biopharma startup headquartered in Pudong’s Zhangjiang Hi-Tech Park, develops novel therapies targeting oncogenic transcription complexes for hard-to-treat cancers. Pipeline:
- KY-001: First-in-class TEAD-YAP inhibitor cleared by FDA/NMPA for clinical trials.
- KY-002: Preclinical allosteric inhibitor disrupting transcription factor/DNA complexes, targeting hematologic/metastatic solid tumors.
The company seeks partnerships, licensing, and investment to accelerate clinical/preclinical programs and expand into next-gen modalities (e.g., protein degraders).
Address
ShanghaiChina
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}